ArticleInflammopharmacology2026
Therapeutic evaluation of myricetin in experimental arthritis: modulation of inflammatory signaling and oxidative stress pathways.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis is a chronic, immune-mediated inflammatory disorder characterized by persistent synovial inflammation, progressive cartilage destruction, and bone erosion. Oxidative stress and excessive production of pro-inflammatory cytokines play central roles in its pathogenesis. Myricetin, a naturally occurring flavonoid, has gained attention for its anti-inflammatory and antioxidant properties. The present study evaluated the therapeutic potential of myricetin in complete Freund's adjuvant-induced arthritis in Wistar rats. Animals were randomly divided into six groups: control, arthritic control, methotrexate treated (0.5 mg/kg), and three myricetin treated groups (1, 2.5, and 5 mg/kg). Arthritis was induced in all experimental groups except the normal control by a single intra-articular injection of 0.2 ml CFA into the ankle joint of the left hind paw. Therapeutic intervention with methotrexate and the respective doses of myricetin was started on day 8 after induction and continued once daily for 21 consecutive days. Disease progression was assessed by body weight monitoring and arthritic scoring. Hematological parameters, rheumatoid factor, nitric oxide (NO), superoxide dismutase (SOD), and catalase levels were measured. The mRNA expression of IL-1β, IL-6, IL-17, TNF-α, and NF-κB was analyzed, and histopathological changes were examined using H&E staining. Myricetin significantly attenuated arthritic severity and leukocyte counts, enhanced antioxidant enzymes levels and downregulated the expression of pro-inflammatory cytokines and NF-κB. Histological findings further confirmed reduced synovial inflammation and attenuation of bone damage. These findings suggest that myricetin alleviates experimental arthritis, possibly through modulation of inflammatory mediators and oxidative stress pathways. However, further mechanistic and translational studies are required to establish its therapeutic efficacy and clinical relevance.
Indexed as
Identifiers
42393478What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.